Home
/
ELITE PHARMACEUTICALS INC /NV/
/
Financials
/
Quarterly
ELITE PHARMACEUTICALS INC /NV/ — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ELITE PHARMACEUTICALS INC /NV/ filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2021
Dec 31, 2020
$6.05M
Feb 16, 2021
Q2
2021
Sep 30, 2020
$7.40M
Nov 16, 2020
Q1
2021
Jun 30, 2020
$7.54M
Aug 14, 2020
Q3
2021
Dec 31, 2019
$5.06M
Feb 16, 2021
Q2
2021
Sep 30, 2019
$4.63M
Nov 16, 2020
Q1
2021
Jun 30, 2019
$3.36M
Aug 14, 2020
Q3
2020
Dec 31, 2018
$2.69M
Feb 10, 2020
Q2
2020
Sep 30, 2018
$1.36M
Nov 12, 2019
Q1
2020
Jun 30, 2018
$2.17M
Aug 9, 2019
Q3
2019
Dec 31, 2017
$2.54M
Feb 11, 2019
Q2
2019
Sep 30, 2017
$1.62M
Nov 9, 2018
Q1
2019
Jun 30, 2017
$1.70M
Aug 9, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2026
Dec 31, 2025
$31.59M
Feb 17, 2026
Q2
2026
Sep 30, 2025
$36.32M
Nov 14, 2025
Q1
2026
Jun 30, 2025
$40.21M
Aug 14, 2025
Q3
2026
Dec 31, 2024
$14.36M
Feb 17, 2026
Q2
2026
Sep 30, 2024
$18.88M
Nov 14, 2025
Q1
2026
Jun 30, 2024
$18.80M
Aug 14, 2025
Q3
2025
Dec 31, 2023
$15.54M
Feb 13, 2025
Q2
2025
Sep 30, 2023
$14.16M
Nov 14, 2024
Q1
2025
Jun 30, 2023
$8.98M
Aug 14, 2024
Q3
2024
Dec 31, 2022
$9.25M
Feb 14, 2024
Q2
2024
Sep 30, 2022
$8.59M
Nov 14, 2023
Q1
2024
Jun 30, 2022
$7.67M
Aug 14, 2023
Q3
2023
Dec 31, 2021
$8.97M
Feb 14, 2023
Q2
2023
Sep 30, 2021
$8.56M
Nov 14, 2022
Q1
2023
Jun 30, 2021
$7.06M
Aug 15, 2022
Q3
2022
Dec 31, 2020
$6.05M
Feb 14, 2022
Q2
2022
Sep 30, 2020
$7.40M
Nov 15, 2021
Q1
2022
Jun 30, 2020
$7.54M
Aug 16, 2021
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Dec 31, 2017
$2.54M
Feb 9, 2018
Q2
2018
Sep 30, 2017
$1.62M
Nov 9, 2017
Q1
2018
Jun 30, 2017
$1.70M
Aug 9, 2017
Q3
2018
Dec 31, 2016
$2.33M
Feb 9, 2018
Q2
2018
Sep 30, 2016
$2.69M
Nov 9, 2017
Q1
2018
Jun 30, 2016
$3.27M
Aug 9, 2017
Q3
2017
Dec 31, 2015
$2.19M
Feb 9, 2017
Q2
2017
Sep 30, 2015
$2.95M
Nov 9, 2016
Q1
2017
Jun 30, 2015
$2.16M
Aug 9, 2016
Q3
2016
Dec 31, 2014
$1.36M
Feb 9, 2016
Q2
2016
Sep 30, 2014
$1.26M
Dec 30, 2015
Q1
2016
Jun 30, 2014
$1.16M
Dec 30, 2015
Q3
2015
Dec 31, 2013
$1.69M
Feb 17, 2015
Q2
2015
Sep 30, 2013
$1.16M
Nov 14, 2014
Q1
2015
Jun 30, 2013
$721.7K
Aug 14, 2014
Q3
2013
Dec 31, 2012
$667.7K
Feb 14, 2014
Q2
2013
Sep 30, 2012
$634.5K
Nov 14, 2013
Q1
2013
Jun 30, 2012
$578.6K
Aug 14, 2013
Q3
2012
Dec 31, 2011
$509.9K
Feb 14, 2013
Q2
2012
Sep 30, 2011
$274.1K
Nov 14, 2012
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2026
Dec 31, 2025
$18.59M
Feb 17, 2026
Q2
2026
Sep 30, 2025
$13.70M
Nov 14, 2025
Q3
2026
Sep 30, 2025
$13.70M
Feb 17, 2026
Q1
2026
Jun 30, 2025
($5.88M)
Aug 14, 2025
Q2
2026
Jun 30, 2025
($5.88M)
Nov 14, 2025
Q3
2026
Jun 30, 2025
($5.88M)
Feb 17, 2026
Q3
2026
Dec 31, 2024
($10.89M)
Feb 17, 2026
Q3
2026
Sep 30, 2024
($11.04M)
Feb 17, 2026
Q2
2026
Sep 30, 2024
($11.04M)
Nov 14, 2025
Q1
2026
Jun 30, 2024
$615.8K
Aug 14, 2025
Q2
2026
Jun 30, 2024
$615.8K
Nov 14, 2025
Q3
2026
Jun 30, 2024
$615.8K
Feb 17, 2026
Q3
2025
Dec 31, 2023
$706.4K
Feb 13, 2025
Q2
2025
Sep 30, 2023
$14.93M
Nov 14, 2024
Q3
2025
Sep 30, 2023
$14.93M
Feb 13, 2025
Q2
2025
Jun 30, 2023
$1.14M
Nov 14, 2024
Q1
2025
Jun 30, 2023
$1.14M
Aug 14, 2024
Q3
2025
Jun 30, 2023
$1.14M
Feb 13, 2025
Q3
2024
Dec 31, 2022
$2.97M
Feb 14, 2024
Q2
2024
Sep 30, 2022
$1.52M
Nov 14, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2026
Dec 31, 2025
$9.01M
Feb 17, 2026
Q2
2026
Sep 30, 2025
$8.21M
Nov 14, 2025
Q1
2026
Jun 30, 2025
$21.70M
Aug 14, 2025
Q3
2026
Dec 31, 2024
$1.10M
Feb 17, 2026
Q2
2026
Sep 30, 2024
$3.48M
Nov 14, 2025
Q1
2026
Jun 30, 2024
$3.86M
Aug 14, 2025
Q3
2025
Dec 31, 2023
$3.53M
Feb 13, 2025
Q2
2025
Sep 30, 2023
$1.93M
Nov 14, 2024
Q1
2025
Jun 30, 2023
$1.60M
Aug 14, 2024
Q3
2024
Dec 31, 2022
$1.96M
Feb 14, 2024
Q2
2024
Sep 30, 2022
$1.08M
Nov 14, 2023
Q1
2024
Jun 30, 2022
$1.02M
Aug 14, 2023
Q3
2023
Dec 31, 2021
$1.83M
Feb 14, 2023
Q2
2023
Sep 30, 2021
$1.42M
Nov 14, 2022
Q1
2023
Jun 30, 2021
$965.2K
Aug 15, 2022
Q3
2022
Dec 31, 2020
$1.00M
Feb 14, 2022
Q2
2022
Sep 30, 2020
$1.34M
Nov 15, 2021
Q1
2022
Jun 30, 2020
$830.6K
Aug 16, 2021
Q3
2021
Dec 31, 2019
$691.2K
Feb 16, 2021
Q2
2021
Sep 30, 2019
($454.5K)
Nov 16, 2020